ANALYSIS: The flurry of takeovers and dearth of new listings shows bold action is needed from policy makers.
Has Xero thrown in the towel in the US?
Shoeshine: Thwarted by underinvestment, can it come back from the brink?
Shoeshine: Glass Lewis thinks Infratil has a diversity problem.
Rocks thrown over passive and active approaches.
Analysis: Will the cutbacks bear fruit?
Analysis: Australian pharmaceuticals distribution is low margin, highly competitive and heavily regulated.